Attached files
| file | filename |
|---|---|
| EX-17 - Bone Biologics Corp | ex-17.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 13, 2017
BONE BIOLOGICS CORPORATION
(Exact name of registrant as specified in its charter)
| Delaware | 000-53078 | 42-1743430 | ||
| (State or other jurisdiction | (Commission | (IRS Employer | ||
| of incorporation) | File Number) | Identification No.) |
| 2 Burlington Woods Drive, Ste. 100 | ||
| Burlington, MA | 01803 | |
| (Address of principal executive offices) | (Zip Code) |
| Registrant’s telephone number, including area code: (732) 661-2224 |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| [ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| [ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| [ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 5.02. | Department of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On April 13, 2017, Dr. Chia Soo and Dr. Ben Wu resigned as directors of the Company. They also resigned as members of Company’s Scientific Advisory Board. The reasons for their resignations are set forth in their notice of resignation which is attached as Exhibit 17. The notice describes their disagreements with the Company.
The Company has provided Drs. Soo and Wu with a copy of the disclosures set forth herein and provided them with an opportunity to furnish to the Company as promptly as possible a letter stating whether they agree with such disclosures and, if not, stating the respects in which he or she does not agree.
The Company’s present Board of Directors has decided to reduce the size of the Board to five members.
| Item 9.01 | Financial Statements and Exhibits |
| (d) | Exhibits. |
There is filed as part of this report the exhibit listed on the accompanying Index to Exhibits, which information is incorporated herein by reference.
| Exhibit No. | Description | |
| 17 | Notice of Resignation |
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: April 19, 2017 | Bone Biologics Corporation | |
| By: | /s/ STEPHEN R. LaNEVE | |
| Name: | Stephen R. LaNeve | |
| Title: | Chief Executive Officer | |
| 3 |
Index to Exhibits
| Exhibit No. | Description | |
| 17 | Notice of Resignation |
| 4 |